MarketPulse

Phase III Orbit study

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Ultragenyx Hit With Class Action Over Setrusumab Data Misrepresentation

Class action lawsuit filed against $UGXY alleging securities fraud over misleading setrusumab trial data and OI patient safety disclosures.
RAREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Ultragenyx Faces Securities Fraud Suit Over Setrusumab Study Misrepresentation

Class action lawsuit filed against $UGXY alleging securities fraud related to setrusumab clinical trial data. Investors from August 2023 to December 2025 eligible.
RAREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Portnoy Law Firm

Portnoy Law Firm Files Securities Class Action Against Ultragenyx Pharmaceutical

Portnoy Law Firm filed securities class action against Ultragenyx Pharmaceutical, alleging the company made false statements about investigational drug setrusumab and concealed material clinical trial risks.
RAREsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Schall Law Firm

Ultragenyx Faces Class Action Over OI Drug Trial Misstatements

Ultragenyx faces class action lawsuit alleging false statements about its osteogenesis imperfecta drug's efficacy after Phase III trial failed to meet primary endpoint.
RAREsecurities fraudclass action lawsuit